Tonghua Dongbao Pharmaceutical Co., Ltd. (TONGHUA DONGBAO MEDICINES CO LT) aksje

Tonghua Dongbao Pharmaceutical Co., Ltd. researches, develops, produces, and markets pharmaceuticals in China. It offers human insulin injections; insulin glargine injections; insulin aspart injections; liraglutide injections; and proprietary Chinese medicine. The company also provides insulin pen and pen needles; and chronic disease management platform, a diabetes management platform for drug treatment, blood glucose monitoring, and patient education. In addition, it offers chemical drugs, such as repaglinide, sitagliptin phosphate, and metformin hydrochloride tablets. Tonghua Dongbao Pharmaceutical Co., Ltd. was founded in 1985 and is headquartered in Tonghua, China.